Make An Appointment Today!

617-573-3202

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

  Reza Dana, M.D., M.P.H., M.Sc.

Dr. Dana is currently doing research in  the MEEI Cornea Service and his lab at the Schepens Eye Research Institute to find new methods to treat the underlying conditions and symptoms of dry eye and blepharitis.  His efforts are focused on finding out exactly how inflammation and immunity contribute to dry eye, and consequently which new therapeutic agents can target the disease mechanism.  His bench to bedside approach brings his discoveries from the lab into the clinics of MEEI allowing patients to have access to state-of-the-art treatments.

Clinical Trials
Dr. Dana’s research team is currently enrolling patients for three clinical studies on dry eye and blepharitis. The first is using a confocal microscope to take detailed images of the cornea to detect changes in the signs of the disorder. This will provide researchers and physicians information on the effects dry eye and blepharitis can have on corneal nerves.  Learn more about this clinical trial.

The second study is to test the effectiveness of anti-inflammatory medicated drops on patients with posterior blepharitis, or inflammation of the inner part of the eyelid.  Patients participating in this study use the study eye drops three times a day for three months. The medication is a synthesized naturally occurring protein in your body that helps to regulate inflammation. By controlling the inflammation in the eyelid it is hoped that the uncomfortable symptoms of blepharitis will diminish. Learn more about this clinical trial.

Another study focused on dry eye is using Restasis, an eye drop commonly used to treat dry eye. Dr. Dana is studying the effects of this eye drop in patients undergoing bone marrow or stem cell transplants. About 50% of patients will develop chronic dry eye disease after their transplant. The research team at MEEI is trying to prevent the development of dry eye disease in this population by using Restasis eye drops before patients develop symptoms or signs of dry eye. Learn more about this clinical trial.

For more information about clinical research studies at MEEI please contact Whitney Howe at 617-391-5894 or Whitney_Howe@meei.harvard.edu.

 

 Learn more about Dr. Dana's work in the lab at Schepen's Eye Research Institute